New modalities of cancer treatment for NSCLC: Focus on immunotherapy

Cancer Management and Research

Volumn 6, Issue 1, 2014, Pages 63-75

  Davies, Marianne ^a  

^a YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Immunotherapy; Ipilimumab; Lung cancer; Nivolumab; Nursing; Vaccination

Indexed keywords

EID: 84893568071     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S57550     Document Type: Review

References (87)

1. American Cancer Society. Cancer facts and figures 2013. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfacts figures2013/index. Updated 2013. Accessed October 8, 2013.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584-594.
3. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-small cell lung cancer. Version 2.2013. Available from: http://www.nccn.com. Updated 2013. Accessed October 8, 2013.
4. Jänne PA, Engelman JA, Johnson BE. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol. 2005;23(14):3227-3234.
5. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Pérez JM. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med Chem. 2007;7(1):3-18.
6. Kwak EL, Bang YJ, Camidge DR, etal. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18): 1693-1703.
7. Paez JG, Jänne PA, Lee JC, etal. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497-1500.
8. Shigematsu H, Lin L, Takahashi T, etal. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339-346.
9. Thunnissen E, Bubendorf L, Dietel M, etal. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461(3):245-257.
10. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16(1):5-24.
11. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
12. Topalian SL, Hodi FS, Brahmer JR, etal. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26): 2443-2454.
13. Wolchok JD, Kluger H, Callahan MK, etal. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
14. Wolchok JD, Neyns B, Linette G, etal. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11(2):155-164.
15. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011;331(6024):1565-1570.
16. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet. 2007;370(9581):59-67.
17. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 2008;224:166-182.
18. Baba T, Hanagiri T, Ichiki Y, etal. Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/B. Cancer Sci. 2007;98(11):1795-1802.
19. Fukuyama T, Ichiki Y, Yamada S, etal. Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci. 2007;98(7):1048-1054.
20. Jadus MR, Natividad J, Mai A, etal. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev Immunol. 2012;2012: 160724.
21. Niehans GA, Brunner T, Frizelle SP, etal. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57(6):1007-1012.
22. Petersen RP, Campa MJ, Sperlazza J, etal. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer. 2006;107(12):2866-2872.
23. Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010;5(5):585-590.
24. Yervoy® (ipilimumab) [package insert]. Princeton, NJ, USA: Bristol-Myers Squibb Company; 2013.
25. Hodi FS, O'Day SJ, McDermott DF, etal. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
26. Provenge® (ipilimumab) [package insert]. Seattle, WA, USA: Dendreon Corporation; 2011.
27. Kantoff PW, Higano CS, Shore ND, etal. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5): 411-422.
28. Al-Shibli KI, Donnem T, Al-Saad S, Persson M, Bremnes RM, Busund LT. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res. 2008;14(16): 5220-5227.
29. Dieu-Nosjean MC, Antoine M, Danel C, etal. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410-4417.
30. Hiraoka K, Miyamoto M, Cho Y, etal. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer. 2006;94(2):275-280.
31. Zhuang X, Xia X, Wang C, etal. A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol. 2010;18(1):24-28.
32. Takanami I, Takeuchi K, Giga M. The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg. 2001;121(6):1058-1063.
33. Villegas FR, Coca S, Villarrubia VG, etal. Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 2002;35(1):23-28.
34. Dasanu CA, Sethi N, Ahmed N. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther. 2012;12(7):923-937.
35. Platonova S, Cherfils-Vicini J, Damotte D, etal. Profound coordinated alterations of intratumoral natural killer cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412-5422.
36. Schneider T, Hoffmann H, Dienemann H, etal. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol. 2011;6(7):1162-1168.
37. Schneider T, Kimpfler S, Warth A, etal. Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma. J Thorac Oncol. 2011;6(3): 432-438.
38. Wang R, Lu M, Zhang J, etal. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res. 2011;30:62.
39. Zeni E, Mazzetti L, Miotto D, etal. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J. 2007;30(4):627-632.
40. Hanna N, Shepherd FA, Fossella FV, etal. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22(9): 1589-1597.
41. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-2531.
42. Xalkori® (crizotinib) [package insert]. New York, NY, USA: Pfizer; 2013.
43. Pallis AG, Fennell DA, Szutowicz E, Leighl NB, Greillier L, Dziadziuszko R. Biomarkers of clinical benefit for anti-epidermal growth factor receptor agents in patients with non-small-cell lung cancer. Br J Cancer. 2011;105(1):1-8.
44. Shepherd FA, Rodrigues PJ, Ciuleanu T, etal. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2): 123-132.
45. Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther Adv Med Oncol. 2011;3(6):279-291.
46. Sandler A, Gray R, Perry MC, etal. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
47. Sienel W, Varwerk C, Linder A, etal. Melanoma associated antigen (MAGE)-A3 expression in Stages I and II non-small cell lung cancer: results of a multi-center study. Eur J Cardiothorac Surg. 2004;25(1): 131-134.
48. Vansteenkiste JF, Zielinski M, Linder A, etal. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;43:Abstr 7103.
49. GlaxoSmithKline. GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/show/NCT00480025. NLM identifier NCT00480025. Accessed December 11, 2013.
50. Reck M, Vansteenkiste J, Brahmer JR. Targeting the immune system for management of NSCLC: the revival? Curr Respir Care Rep. 2013;2(1):22-39.
51. Butts C, Murray N, Maksymiuk A, etal. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005;23(27):6674-6681.
52. EMD Serono. Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START). Available from: http://clinicaltrials.gov/ct2/show/NCT00409188. NLM identifier: NCT00409188. Accessed December 11, 2013.
53. Merck KGaA. Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE). Available from: http://clinicaltrials.gov/ct2/show/NCT01015443. NLM identifier: NCT01015443. Accessed December 11, 2013.
54. Quoix E, Ramlau R, Westeel V, etal. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011;12(12): 1125-1133.
55. Transgene. Phase IIB/III of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer (TIME). Available from: http://clinicaltrials.gov/show/NCT01383148. NLM identifier: NCT01383148. Accessed December 11, 2013.
56. Nemunaitis J, Dillman RO, Schwarzenberger PO, etal. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol. 2006;24(29):4721-4730.
57. NovaRx Corporation. Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy (STOP). Available from: http://clinicaltrials.gov/show/NCT00676507. NLM identifier: NCT00676507. Accessed December 11, 2013.
58. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, etal. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(9): 1452-1458.
59. Bioven Europe. A Randomized Trial to Study the Safety and Efficacy of EGF Cancer Vaccination in Late-stage (IIIB/IV) Non-small Cell Lung Cancer Patients (NSCLC). Available from: http://clinicaltrials.gov/show/NCT01444118. NLM identifier: NCT01444118. Accessed December 11, 2013.
60. Margolin KA, Wong SL, Penrod JR, etal. Effectiveness and safety of first-line ipilimumab 3 mg/kg therapy for advanced melanoma: evidence from a US multisite retrospective chart review. Poster 3742 presented at the European Cancer Congress, September 27 to October 1, 2013, Amsterdam, The Netherlands.
61. Patt D, Juday T, Penrod JR, Chen C, Wong SL. A community-based, real-world, study of treatment-naïve advanced melanoma (AM) patients treated with 3 mg/kg ipilimumab (IPI) in the United States. Poster 3751 presented at the European Cancer Congress, September 27 to October 1, 2013, Amsterdam, The Netherlands.
62. Lynch TJ, Bondarenko I, Luft A, etal. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30(17):2046-2054.
63. Bristol-Myers Squibb. Trial in Squamous Non Small Cell Lung Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin. Available from: http://clinicaltrials.gov/show/NCT01285609. NLM identifier: NCT01285609. Accessed December 11, 2013.
64. Hamid O, Carvajal RD. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther. 2013;13(6):847-861.
65. Brahmer JR, Horn L, Antonia SJ, etal. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. Abstract MO18.03 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
66. Bristol-Myers Squibb. Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017). Available from: http://clinicaltrials.gov/show/NCT01642004. NLM identifier: NCT01642004. Accessed December 11, 2013.
67. Bristol-Myers Squibb. Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate 057). Available from: http://clinicaltrials.gov/show/NCT01673867. NLM identifier: NCT01673867. Accessed December 11, 2013.
68. Bristol-Myers Squibb. Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens (CheckMate 063). Available from: http://clinicaltrials.gov/show/NCT01721759. NLM identifier: NCT01721759. Accessed December 11, 2013.
69. Bristol-Myers Squibb. A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors. Available from: http://clinicaltrials.gov/show/NCT01928394. NLM identifier: NCT01928394. Accessed December 11, 2013.
70. Sidney Kimmel Comprehensive Cancer Center. Phase II Anti-PD1 Epigenetic Priming Study in NSCLC. (NA_00084192). Available from: http://clinicaltrials.gov/show/NCT01928576. NLM identifier: NCT01928576. Accessed December 11, 2013.
71. Bristol-Myers Squibb. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012). Available from: http://clinicaltrials.gov/show/NCT01454102. NLM identifier: NCT01454102. Accessed December 11, 2013.
72. Hamid O, Robert C, Daud A, etal. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2): 134-144.
73. Garon EB, Balmanoukian A, Hamid O, etal. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). Abstract MO18.02 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
74. Merck. Study of Two Doses of MK-3475 Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010). Available from: http://clinicaltrials.gov/show/NCT01905657. NLM identifier: NCT01905657. Accessed December 11, 2013.
75. Brahmer JR, Tykodi SS, Chow LQ, etal. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
76. Horn L, Herbst RS, Spigel DR, etal. An analysis of the relationship of clinical activity to baseline EGFR status, PD-L1 expression and prior treatment history in patients with non-small cell lung cancer (NSCLC) following PD-L1 blockade with MPDL3280A (anti-PDL1). Abstract MO18.01 presented at the 15th International Association for the Study of Lung Cancer World Conference on Lung Cancer, October 27-30, 2013, Sydney, Australia.
77. Genentech. A Study Of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer. Available from: http://clinicaltrials.gov/show/NCT01846416. NLM identifier: NCT01846416. Accessed December 11, 2013.
78. Hoffmann-La Roche. A Study of MPDL3280A Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer After Platinum Failure. Available from: http://clinicaltrials.gov/show/NCT01903993. NLM identifier: NCT01903993. Accessed December 11, 2013.
79. Bristol-Myers Squibb. Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012). Available from: http://clinicaltrials.gov/show/NCT01454102. NLM identifier: NCT01454102. Accessed December 11, 2013.
80. Bristol-Myers Squibb. Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors. Available from: http://clinicaltrials.gov/show/NCT01629758. NLM identifier: NCT01629758. Accessed December 11, 2013.
81. Bristol-Myers Squibb. A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors. Available from: http://clinicaltrials.gov/show/NCT01714739. NLM identifier: NCT01714739. Accessed December 11, 2013.
82. ClinicalTrials. gov. [homepage on the Internet]. US National Institutes of Health. Updated 2013. Available from: http://clinicaltrials.gov/. Accessed October 8, 2013.
83. Wolchok JD, Hoos A, O'Day S, etal. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412-7420.
84. Prieto PA, Yang JC, Sherry RM, etal. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18(7):2039-2047.
85. Herbst RS, Gordon MS, Fine GD, etal. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31 Suppl:Abstr 3000.
86. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-2697.
87. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007;12(7):864-872.